NBL-028
/ CSPC Pharma, NovaRock Biotherapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
March 18, 2024
NBL-028-001: A Study of NBL-028 in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=270 | Recruiting | Sponsor: NovaRock Biotherapeutics, Ltd | Not yet recruiting ➔ Recruiting
Enrollment open • Metastases • Oncology • Solid Tumor
January 25, 2024
A Study of NBL-028 in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=270 | Not yet recruiting | Sponsor: NovaRock Biotherapeutics, Ltd
Metastases • New P1 trial • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1